CRISPR Zugo-cel Shows Promise in Autoimmune Trial
Early data from CRISPR Therapeutics' gene-edited CAR-T therapy show responses across lupus, scleroderma and inflammatory myopathy patients.
Global Biotech News
Reporting here follows biotechnology — gene editing, genomics, drug development platforms, clinical trial results and the investment and regulatory activity shaping how biological research becomes commercial product. Coverage spans the science, the deal-making and the regulatory proceedings that determine what reaches patients and when.
Recent news
November 8, 2026
Puma Cuts Royalty Guidance as Generics Gain ChinaThe biotech reported $55.1 million in third-quarter revenue and became debt-free after its final loan payment.
November 7, 2026
Study Finds Europe's Tech Transfer Offices Lag PeersA survey of 809 offices shows large institutions hold most capacity while small offices struggle to convert research into patents.
November 6, 2026
CRISPR Therapy Durably Lowers ANGPTL3 in PrimatesA single-dose base-editing treatment cut circulating ANGPTL3 protein by more than 90% in nonhuman primates, with effects lasting three years.
November 6, 2026
Adalvo Acquires Enzene's Romiplostim Biosimilar ProgramThe deal transfers a biosimilar candidate referencing Amgen's NPLATE, a treatment for immune thrombocytopenia, to Adalvo.
November 6, 2026
Moderna Settles GSK Patent Suits Over VaccinesModerna and GSK agreed to cross-licenses in infectious disease and asked a Delaware court to dismiss GSK's US claims.
November 6, 2026
Moderna Scraps Norovirus Vaccine Cohort EnrollmentThe company will meet with regulators to decide next steps for its mRNA-1403 phase 3 trial after cutting plans for a new cohort.
November 6, 2026
Novo Ends Korro Bio Collaboration Effective 2027Novo Nordisk has elected to terminate its cardiometabolic research deal with Korro Bio, with the termination set to take effect February 1, 2027.
November 6, 2026
SOTIO Reports 59% Disease Control in Solid TumorsInterim Phase 1 data for SOT201 in advanced solid tumor patients were presented at the SITC 41st Annual Meeting in Phoenix, AZ.
November 6, 2026
Brieno Model Decodes Raw Nanopore SignalsA self-supervised Transformer pretrained on raw nanopore sequencing signals can classify species and detect DNA methylation without reference genomes.
November 6, 2026
Israeli Firms Open ScaIL UK 2027 ApplicationsThe British Embassy opened applications for the 2027 cohort of a government-backed program helping Israeli technology companies expand into the United Kingdom.
More in Biotech
Statewide reporting centres on clinical trial results and their implications, regulatory submissions and decisions, biotech IPOs and secondary offerings, acquisition activity, partnership agreements between biotech firms and larger pharmaceutical companies and the platform technologies that define each investment cycle. The relationship between biotech and large pharmaceutical companies — where the latter increasingly acquires rather than internally develops new drugs — has made deal coverage central to the biotech beat. Regulatory decisions carry outsized market and coverage weight in biotech because a single approval or rejection can validate or undermine a platform that multiple companies have built around. Gene therapy and RNA-based platforms have generated their own sustained coverage tracks as they have moved from proof-of-concept to approved therapies, with each new approval extending the story into access and pricing territory.